Navigation Links
Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
Date:7/10/2012

SAN DIEGO, July 10, 2012 /PRNewswire/ -- Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors.  Published today in Cancer Cell, the findings show that Cylene's Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant but not in normal cells.

The researchers repeated these studies with in vivo models of blood cancers and demonstrated that the drug removed malignant cells from the bloodstream, while allowing normal healthy blood cells to grow, thus differentiating CX-5461 from genotoxic treatments. Targeting cancer's dependence upon Pol I to trigger cancer-specific activation of p53 signifies an entirely new approach to cancer therapy.

"The Pol I program represents the total package. Dr. Ross Hannan, Associate Professor and Group Leader at Peter Mac's Growth Regulation Laboratory, performed elegant studies to validate Pol I as a cancer target, Cylene created CX-5461 as the first selective small molecule inhibitor of Pol I, and together we showed that this approach potently kills malignant cells through activation of p53," stated William G. Rice, PhD, President and CEO of Cylene Pharmaceuticals. "Building on our mechanistic understanding of CX-5461, we have identified specific genetic markers to select patient populations with the most sensitive solid tumor or hematological cancers."

"The combination of cancer's reliance on Pol I, the impressive preclinical activity of CX-5461, the development of clear predictive and prognostic biomarkers and the novelty of the therapeutic strategy is compelling," continued Dr. Rice.  "As such, a First-in-Human clinical trial with CX-5461 is planned in collaboration with our colleagues at Peter M
'/>"/>

SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
2. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
3. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
4. Global Kidney Cancer Drugs Industry
5. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
6. Prostate Cancer Center of New Jersey the Latest Center to Achieve High Honor of ACR-ASTRO Accreditation
7. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
8. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
9. Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
10. Elektas Gamma Knife and Radiation Therapy Systems for Cancer Treatment Take Top Three Places in 2012s Best in KLAS for Radiation Therapy
11. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Today the U.S. Food and Drug ... the prevention of serogroup B meningococcal disease ... vaccine Trumenba®, which received FDA approval in October, represent ... disease. "I have heard over and ...
(Date:1/23/2015)... WASHINGTON , Jan. 23, 2015  A new analysis ... Part D 2015 enrollment data shows that 81 percent ... convenient access and extra discounts at certain pharmacies. The ... "Preferred pharmacy plans are now the foundation of ...
(Date:1/23/2015)... Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) ... of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... its fiduciary duties to shareholders. On January ... website reporting that Advaxis had misrepresented the clinical data ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... Adherence to strict outcome requirements imposed by the ... an adverse effect on liver transplantation centers performing ... according to researchers at Northwestern University. According to ... aim to enhance post-transplant outcomes, the inadequately risk-adjusted ...
... 5, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... further clarity and context surrounding the risk for ... with KRYSTEXXA® (pegloticase) in the treatment of refractory ... the American College of Rheumatology (ACR) Annual Scientific ...
Cached Medicine Technology:Study Calls for Modification of CMS Conditions of Participation to Preserve Access to Life-Saving Liver Transplantations under Less than Optimal Conditions 2Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 2Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 3Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 4Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 5Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 6Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 7Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 8
(Date:1/22/2015)... 2015 Deer Path of Huntley -- ... Day Happy Hour from 3 p.m. to 4 p.m. on Feb. ... in Huntley, Illinois, serves adults with physical disabilities between the ages ... Valentine's Day treats, games and sweetheart-themed karaoke. , For more information ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 The City of ... at 10 a.m., to commemorate the 42nd anniversary of the Supreme ... States. , “It’s been 42 years since the Roe vs. Wade ... is still as present as ever,” said City of West Hollywood ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader ... designers are thrilled to have it lead the wedding dress ... collection of prom dresses for the global market. , “The ... vision and he focuses on continuing the goal of operational ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... WASHINGTON, July 31 Speaker Nancy Pelosi issued the following statement ... to pass the America,s Affordable Health Choices Act, the third House ... and Means Committee and Education and Labor Committee approved the bill ... than 60 years, we have tried as a nation to make ...
... , WASHINGTON, July 31 ... "The Importance of a Cost Control Enforcement Entity In ... President Obama,s proposed Independent Medicare Advisory Council (IMAC). The ... experts who would routinely review Medicare spending and provide ...
... childhood cancer neuroblastoma are eight times more likely to ... and more likely to have lower incomes than their ... in the Journal of the National Cancer Institute ... exists on the long-term outcomes for neuroblastoma survivors. ...
... Hanger Orthopedic Group, Inc. (NYSE: HGR ) is ... Hanger Orthopedic Group, Inc. to "B1" from "B2." Moody,s also ... "Ba2" from "Ba3" and senior unsecured debt to "B3" from "Caa1." ... , "We are extremely pleased with the Moody,s upgrade ...
... , WASHINGTON, July 31 On behalf ... Kathleen Novak, mayor, Northglenn, Colo., commends President Barack Obama, the ... Pensions Committee for making progress on efforts to enact legislation ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NLCLOGO ) , ...
... and social issues years later , FRIDAY, July 31 (HealthDay ... long-term health and social problems, according to a new study. ... been diagnosed with neuroblastoma -- a cancer that forms in ... with data on 3,899 siblings of children with cancer. Twenty ...
Cached Medicine News:Health News:Concord Coalition Releases Issue Brief on Administration's IMAC Proposal 2Health News:Long-term health and social outcomes for neuroblastoma survivors 2Health News:Hanger Orthopedic Group, Inc. Receives Upgrade From Moody's Investors Service 2Health News:National League of Cities Commends President and Congress on Work Towards Health Care Reform 2
... ScImage's PICOMEnterprise is a web-enabled ... custom reporting and custom workflow integration. ... captures, stores, distributes and archives images, ... any DICOM and many non-DICOM devices ...
... Blood Pressure Monitoring System (ABPM) allows health ... blood pressure throughout the day. ABPM therapy ... hypertension and the data generated can be ... compact monitor has sophisticated tracking capabilities to ...
... AutoPulse Resuscitation System consists of the portable ... and a rechargeable battery pack with a ... designed for adults with weight up to ... to 51.2 inches (76 to 130 cm) ...
... single information technology platform, the VERICIS ... from different sites (office, clinic, hospital) ... x-ray angiography, echo, nuclear, MR, hemodynamics, ... digital record on the cardiac patient. ...
Medicine Products: